HEPATIC AMOEBIASIS

HEPATIC AMOEBIASIS was reported 67 times

HEPATIC AMOEBIASIS is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Dihydrofolate Reductase Inhibitor Antimalarial [EPC] 6 0.0047
1 Antimalarial [EPC] 6 0.0006
2 Antiprotozoal [EPC] 6 0.0006
3 SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor [EPC] 5 0.0004
4 Antimetabolite Immunosuppressant [EPC] 5 0.0002
5 Nitroimidazole Antimicrobial [EPC] 13 0.0002
6 Lipopeptide Antibacterial [EPC] 1 0.0001
7 Protease Inhibitor [EPC] 3 0.0001
8 Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] 3 0.0001
9 Nucleoside Analog Antiviral [EPC] 5 0.0001
10 Penem Antibacterial [EPC] 2 0.0001
11 Cytochrome P450 3A Inhibitor [EPC] 3 0.0000
12 Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC] 1 0.0000
13 Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] 1 0.0000
14 Antimycobacterial [EPC] 1 0.0000
15 Fluoroquinolone Antibacterial [EPC] 5 0.0000
16 CD20-directed Cytolytic Antibody [EPC] 12 0.0000
17 Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] 4 0.0000
18 Alkylating Drug [EPC] 8 0.0000
19 Purine Antimetabolite [EPC] 3 0.0000
20 Platinum-based Drug [EPC] 6 0.0000
21 Dihydrofolate Reductase Inhibitor Antibacterial [EPC] 2 0.0000
22 Corticosteroid [EPC] 26 0.0000
23 Cardiac Glycoside [EPC] 1 0.0000
24 Azole Antifungal [EPC] 2 0.0000
25 Microtubule Inhibitor [EPC] 2 0.0000
26 Interleukin-12 Antagonist [EPC] 1 0.0000
27 Interleukin-23 Antagonist [EPC] 1 0.0000
28 Nucleoside Metabolic Inhibitor [EPC] 2 0.0000
29 Tumor Necrosis Factor Blocker [EPC] 7 0.0000
30 Expectorant [EPC] 1 0.0000
31 Osmotic Laxative [EPC] 1 0.0000
32 Vitamin D [EPC] 1 0.0000
33 Angiotensin 2 Receptor Blocker [EPC] 1 0.0000
34 Vitamin B12 [EPC] 1 0.0000
35 Vitamin C [EPC] 1 0.0000
36 Thalidomide Analog [EPC] 1 0.0000
37 Nonsteroidal Anti-inflammatory Drug [EPC] 2 0.0000
38 Benzodiazepine [EPC] 1 0.0000